🇺🇸 FDA
Pipeline program

A-101 Solution 40

A-101-WART-201

Phase 2 small_molecule completed

Quick answer

A-101 Solution 40 for Common Warts is a Phase 2 program (small_molecule) at Aclaris Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Aclaris Therapeutics
Indication
Common Warts
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials